ONCY
Oncolytics Biotech Inc.1.0400
+0.1170+12.7%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
111.91MP/E (TTM)
-Basic EPS (TTM)
-0.29Dividend Yield
0%Recent Filings
8-K
8-K
Oncolytics appoints key execs
Oncolytics Biotech appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as VP, Head of Biostatistics, on January 14, 2026, to bolster late-stage clinical execution in pancreatic, colorectal, and anal cancer programs. Both bring proven oncology trial expertise from CG Oncology and Morphic Therapeutic. Inducement awards: McAdory got 500,000 stock options and 300,000 RSUs; Wu, 300,000 options—all at $0.97 strike. Leadership bolsters regulatory push.
8-K
Shareholders approve Nevada domestication
Oncolytics Biotech shareholders approved on January 15, 2026, a two-step move from Alberta to British Columbia, then to Nevada, plus the 2026 Incentive Award Plan, with votes exceeding 76% for each. Resolutions passed handily: 85% for continuance, 87% for domestication. This streamlines regulatory and operational processes. Expected to close by end of Q1 2026.
8-K
Pelareorep IP, anal cancer data
Oncolytics disclosed IP updates for pelareorep, including a Track 1 USPTO manufacturing patent filed Q3 2025 with final action expected Q3 2026, potentially extending protection to 2044, plus planned filings beyond. GOBLET Cohort 4 data showed 29% ORR and 17-month median DOR in third-line anal cancer, nearly tripling historical 10% benchmarks in an unmet need area. Registration study planned post-FDA Type C meeting Q1 2026.
IPO
Employees
Sector
Industry
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CGON
CG Oncology, Inc.
37.85-1.90
CRDF
Cardiff Oncology, Inc.
2.40-0.01
CYDY
CytoDyn Inc.
0.32+0.02
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
OLMA
Olema Pharmaceuticals, Inc.
34.28-1.55
ONC
BeOne Medicines Ltd.
304.31-6.36
ONCO
Onconetix, Inc.
1.94-0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
REPL
Replimune Group, Inc.
9.61-0.34